DK2358675T3 - 4-[2-(2-Fluorphenoxymethyl)phenyl]piperidinforbindelser - Google Patents
4-[2-(2-Fluorphenoxymethyl)phenyl]piperidinforbindelserInfo
- Publication number
- DK2358675T3 DK2358675T3 DK09752688.3T DK09752688T DK2358675T3 DK 2358675 T3 DK2358675 T3 DK 2358675T3 DK 09752688 T DK09752688 T DK 09752688T DK 2358675 T3 DK2358675 T3 DK 2358675T3
- Authority
- DK
- Denmark
- Prior art keywords
- fluorophenoxymethyl
- piperidine
- phenyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
- C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Psychology (AREA)
- Physical Education & Sports Medicine (AREA)
- Reproductive Health (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Child & Adolescent Psychology (AREA)
- Gynecology & Obstetrics (AREA)
- Addiction (AREA)
- Nutrition Science (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11454108P | 2008-11-14 | 2008-11-14 | |
PCT/US2009/064308 WO2010056941A1 (en) | 2008-11-14 | 2009-11-13 | 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2358675T3 true DK2358675T3 (da) | 2013-01-14 |
Family
ID=41666409
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK09752687.5T DK2358674T3 (da) | 2008-11-14 | 2009-11-13 | Fremgangsmåde til fremstilling af 4-[2-(2-fluorphenoxymethyl)phenyl]piperidinforbindelser |
DK09752988.7T DK2358676T3 (da) | 2008-11-14 | 2009-11-13 | Krystallinsk form af en 4-[2-(2-fluorphenoxymethyl)phenyl]-piperidinforbindelse |
DK09752688.3T DK2358675T3 (da) | 2008-11-14 | 2009-11-13 | 4-[2-(2-Fluorphenoxymethyl)phenyl]piperidinforbindelser |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK09752687.5T DK2358674T3 (da) | 2008-11-14 | 2009-11-13 | Fremgangsmåde til fremstilling af 4-[2-(2-fluorphenoxymethyl)phenyl]piperidinforbindelser |
DK09752988.7T DK2358676T3 (da) | 2008-11-14 | 2009-11-13 | Krystallinsk form af en 4-[2-(2-fluorphenoxymethyl)phenyl]-piperidinforbindelse |
Country Status (29)
Country | Link |
---|---|
US (22) | US8304433B2 (da) |
EP (3) | EP2358676B1 (da) |
JP (6) | JP5506813B2 (da) |
KR (3) | KR101656338B1 (da) |
CN (3) | CN102209712B (da) |
AR (3) | AR074128A1 (da) |
AU (3) | AU2009313948B2 (da) |
BR (3) | BRPI0921596B1 (da) |
CA (3) | CA2742105C (da) |
CL (2) | CL2011001088A1 (da) |
CO (2) | CO6361988A2 (da) |
CY (3) | CY1113622T1 (da) |
DK (3) | DK2358674T3 (da) |
ES (3) | ES2401224T3 (da) |
HK (3) | HK1160449A1 (da) |
HR (3) | HRP20120897T1 (da) |
IL (2) | IL212230A (da) |
MX (3) | MX2011005089A (da) |
MY (2) | MY151229A (da) |
NZ (2) | NZ592413A (da) |
PL (3) | PL2358676T3 (da) |
PT (3) | PT2358675E (da) |
RU (2) | RU2503662C2 (da) |
SG (1) | SG171311A1 (da) |
SI (3) | SI2358675T1 (da) |
SM (3) | SMT201200063B (da) |
TW (3) | TWI443087B (da) |
WO (3) | WO2010056938A1 (da) |
ZA (1) | ZA201103495B (da) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2358674T3 (da) | 2008-11-14 | 2013-04-08 | Theravance Inc | Fremgangsmåde til fremstilling af 4-[2-(2-fluorphenoxymethyl)phenyl]piperidinforbindelser |
JP5705239B2 (ja) | 2010-01-11 | 2015-04-22 | セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー | セロトニンおよびノルエピネフリン再取込みインヒビターとしての1−(2−フェノキシメチルフェニル)ピペラジン化合物 |
JP5769348B2 (ja) * | 2010-03-22 | 2015-08-26 | セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー | 1−(2−フェノキシメチルヘテロアリール)ピペリジン化合物および1−(2−フェノキシメチルヘテロアリール)ピペラジン化合物 |
ES2532204T3 (es) * | 2010-04-22 | 2015-03-25 | Theravance Biopharma R&D Ip, Llc | Combinación de un inhibidor de la recaptación de serotonina y norepinefrina y un agonista opioide para el tratamiento de dolor |
CA2830882C (en) | 2011-03-22 | 2021-03-16 | Dinesh Barawkar | Substituted fused tricyclic compounds, compositions and medicinal applications thereof |
US9544692B2 (en) * | 2012-11-19 | 2017-01-10 | Bitwave Pte Ltd. | System and apparatus for boomless-microphone construction for wireless helmet communicator with siren signal detection and classification capability |
JP6853345B2 (ja) * | 2016-08-30 | 2021-03-31 | セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー | 神経原性起立性低血圧の処置に使用するための化合物 |
ES2960492T3 (es) * | 2018-06-01 | 2024-03-05 | Theravance Biopharma R&D Ip Llc | Procedimiento para la preparación de ácido 2-(1-(terc-butoxicarbonil)piperidín-4-il)benzoico |
US20230372318A1 (en) | 2022-03-28 | 2023-11-23 | Theravance Biopharma R&D Ip, Llc | Methods for treating a subject having multiple system atrophy |
CN114957098B (zh) * | 2022-06-02 | 2024-03-29 | 和鼎(南京)医药技术有限公司 | 一种制备喷他佐辛中间体的方法 |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1422263A (en) | 1973-01-30 | 1976-01-21 | Ferrosan As | 4-phenyl-piperidine compounds |
DE2549999A1 (de) * | 1975-11-07 | 1977-05-12 | Boehringer Mannheim Gmbh | Piperidin-derivate und verfahren zu ihrer herstellung |
US4241071A (en) | 1977-01-27 | 1980-12-23 | American Hoechst Corporation | Antidepressant (α-phenyl-2-tolyl)azacycloalkanes |
IL56369A (en) | 1978-01-20 | 1984-05-31 | Erba Farmitalia | Alpha-phenoxybenzyl propanolamine derivatives,their preparation and pharmaceutical compositions comprising them |
US4198417A (en) | 1979-01-10 | 1980-04-15 | American Hoechst Corporation | Phenoxyphenylpiperidines |
EP0190496A3 (en) | 1984-12-13 | 1987-05-27 | Beecham Group Plc | Piperidine derivatives having a gastro-intestinal activity |
US4956388A (en) * | 1986-12-22 | 1990-09-11 | Eli Lilly And Company | 3-aryloxy-3-substituted propanamines |
DE3835291A1 (de) * | 1988-04-19 | 1989-11-02 | Bayer Ag | 1,3-disubstituierte pyrrolidine |
GB9324018D0 (en) * | 1993-11-23 | 1994-01-12 | Merck Sharp & Dohme | Therapeutic agents |
JP2002520316A (ja) * | 1998-07-10 | 2002-07-09 | アストラゼネカ・アクチエボラーグ | ニューロキニン受容体アンタゴニストとしてのn−置換ナフタレンカルボキサミド |
GB9922521D0 (en) | 1998-10-07 | 1999-11-24 | Zeneca Ltd | Compounds |
ES2157148B1 (es) * | 1998-11-18 | 2002-03-01 | Faes Fabrica Espanola De Produ | Nuevas piperidinas 4-sustituidas. |
US6518284B2 (en) | 1998-11-18 | 2003-02-11 | Faes, Fabrica Espanola De Productos Quimicos Y Farmaceuticos S.A. | 4-substituted piperidines |
US6770666B2 (en) | 1999-12-27 | 2004-08-03 | Japan Tobacco Inc. | Fused-ring compounds and use thereof as drugs |
CA2363274A1 (en) * | 1999-12-27 | 2001-07-05 | Japan Tobacco Inc. | Fused-ring compounds and use thereof as drugs for hepatitis c |
US6630504B2 (en) | 2000-08-31 | 2003-10-07 | Pfizer Inc. | Phenoxyphenylheterocyclyl derivatives as SSRIs |
US7294637B2 (en) | 2000-09-11 | 2007-11-13 | Sepracor, Inc. | Method of treating addiction or dependence using a ligand for a monamine receptor or transporter |
UA81749C2 (uk) | 2001-10-04 | 2008-02-11 | Х. Луннбек А/С | Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну |
US7384941B2 (en) | 2002-08-23 | 2008-06-10 | Eli Lilly And Company | 2-(phenoxymethyl)-and 2-(phenylthiomethyl)-morpholine derivatives for use as selective norepinephrine reuptake inhibitors |
KR20050119682A (ko) * | 2003-04-04 | 2005-12-21 | 하. 룬트벡 아크티에 셀스카브 | 세로토닌 재흡수 억제제로서 4-(2-페닐옥시페닐)-피페리딘또는 -1,2,3,6-테트라히드로피리딘 유도체 |
ATE392896T1 (de) * | 2003-04-04 | 2008-05-15 | Lundbeck & Co As H | 4-(2-phenyloxyphenyl)-piperidin- oder -1,2,3,6- tetrahydropyridin-derivate als serotonin- wiederaufnahme-hemmer |
PT1638933E (pt) * | 2003-06-17 | 2008-07-22 | Pfizer | Derivados de n-pirrolidin-3-il-amida como inibidores de recaptação de serotonina e noradrenalina |
TW200900399A (en) | 2003-10-01 | 2009-01-01 | Speedel Experimenta Ag | Organic compounds |
US20070105870A1 (en) | 2004-01-13 | 2007-05-10 | Pfizer Inc. | Piperazine derivatives which exhibit activity as serotonin and noradrenaline re-uptake inhibitors |
EP1725518A1 (en) | 2004-03-05 | 2006-11-29 | Eli Lilly And Company | Pharmaceutical compounds |
GEP20084550B (en) | 2004-04-30 | 2008-11-25 | Warner Lambert Co | Substituted morpholine compounds for the treatment of central nervous system disorders |
GB0505437D0 (en) | 2005-03-17 | 2005-04-20 | Merck Sharp & Dohme | Therapeutic agents |
US20070142389A1 (en) * | 2005-12-20 | 2007-06-21 | Pfizer Inc. | Piperidine derivatives |
US20070249607A1 (en) * | 2006-04-17 | 2007-10-25 | Bristol-Myers Squibb Company | Nk-1 and serotonin transporter inhibitors |
JP2010501542A (ja) | 2006-08-23 | 2010-01-21 | ファイザー・プロダクツ・インク | ピペリジン誘導体 |
JP2010512304A (ja) * | 2006-09-27 | 2010-04-22 | メルク・シャープ・エンド・ドーム・コーポレイション | メラノコルチン−4受容体モジュレータとしてのアシル化ピペリジン誘導体 |
US8026257B2 (en) | 2007-07-11 | 2011-09-27 | Bristol-Myers Squibb Company | Substituted heterocyclic ethers and their use in CNS disorders |
WO2009081259A1 (en) | 2007-12-21 | 2009-07-02 | Pfizer Inc. | Phenoxy-pyridyl derivatives |
AU2009271414A1 (en) | 2008-06-20 | 2010-01-21 | Metabolex, Inc. | Aryl GPR119 agonists and uses thereof |
TWI438190B (zh) | 2008-07-24 | 2014-05-21 | Theravance Inc | 3-(苯氧基苯基甲基)吡咯啶化合物 |
DK2358674T3 (da) | 2008-11-14 | 2013-04-08 | Theravance Inc | Fremgangsmåde til fremstilling af 4-[2-(2-fluorphenoxymethyl)phenyl]piperidinforbindelser |
JP5705239B2 (ja) | 2010-01-11 | 2015-04-22 | セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー | セロトニンおよびノルエピネフリン再取込みインヒビターとしての1−(2−フェノキシメチルフェニル)ピペラジン化合物 |
JP5769348B2 (ja) * | 2010-03-22 | 2015-08-26 | セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー | 1−(2−フェノキシメチルヘテロアリール)ピペリジン化合物および1−(2−フェノキシメチルヘテロアリール)ピペラジン化合物 |
JP6853345B2 (ja) * | 2016-08-30 | 2021-03-31 | セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー | 神経原性起立性低血圧の処置に使用するための化合物 |
-
2009
- 2009-11-13 DK DK09752687.5T patent/DK2358674T3/da active
- 2009-11-13 CA CA2742105A patent/CA2742105C/en active Active
- 2009-11-13 MX MX2011005089A patent/MX2011005089A/es active IP Right Grant
- 2009-11-13 PL PL09752988T patent/PL2358676T3/pl unknown
- 2009-11-13 MY MYPI20111690 patent/MY151229A/en unknown
- 2009-11-13 EP EP09752988A patent/EP2358676B1/en active Active
- 2009-11-13 AR ARP090104419A patent/AR074128A1/es active IP Right Grant
- 2009-11-13 JP JP2011536491A patent/JP5506813B2/ja active Active
- 2009-11-13 MX MX2011005088A patent/MX2011005088A/es active IP Right Grant
- 2009-11-13 CN CN200980144708.1A patent/CN102209712B/zh active Active
- 2009-11-13 CA CA2742114A patent/CA2742114C/en active Active
- 2009-11-13 DK DK09752988.7T patent/DK2358676T3/da active
- 2009-11-13 KR KR1020117013512A patent/KR101656338B1/ko active IP Right Grant
- 2009-11-13 SG SG2011035169A patent/SG171311A1/en unknown
- 2009-11-13 US US12/617,838 patent/US8304433B2/en active Active
- 2009-11-13 SI SI200930435T patent/SI2358675T1/sl unknown
- 2009-11-13 CN CN2009801452272A patent/CN102216271B/zh active Active
- 2009-11-13 SI SI200930419T patent/SI2358676T1/sl unknown
- 2009-11-13 PL PL09752687T patent/PL2358674T3/pl unknown
- 2009-11-13 EP EP09752688.3A patent/EP2358675B9/en active Active
- 2009-11-13 NZ NZ592413A patent/NZ592413A/xx unknown
- 2009-11-13 ES ES09752687T patent/ES2401224T3/es active Active
- 2009-11-13 AR ARP090104418A patent/AR074350A1/es not_active Application Discontinuation
- 2009-11-13 KR KR1020117013510A patent/KR101656339B1/ko active IP Right Grant
- 2009-11-13 WO PCT/US2009/064304 patent/WO2010056938A1/en active Application Filing
- 2009-11-13 PT PT97526883T patent/PT2358675E/pt unknown
- 2009-11-13 BR BRPI0921596-4A patent/BRPI0921596B1/pt active IP Right Grant
- 2009-11-13 TW TW098138707A patent/TWI443087B/zh active
- 2009-11-13 BR BRPI0921595A patent/BRPI0921595B8/pt active IP Right Grant
- 2009-11-13 AU AU2009313948A patent/AU2009313948B2/en active Active
- 2009-11-13 JP JP2011536490A patent/JP5598798B2/ja active Active
- 2009-11-13 AU AU2009313951A patent/AU2009313951B2/en active Active
- 2009-11-13 NZ NZ592543A patent/NZ592543A/xx unknown
- 2009-11-13 KR KR1020117013185A patent/KR101685186B1/ko active IP Right Grant
- 2009-11-13 PL PL09752688T patent/PL2358675T3/pl unknown
- 2009-11-13 US US12/617,821 patent/US8304432B2/en active Active
- 2009-11-13 PT PT97526875T patent/PT2358674E/pt unknown
- 2009-11-13 MY MYPI20111925 patent/MY151211A/en unknown
- 2009-11-13 WO PCT/US2009/064306 patent/WO2010056939A1/en active Application Filing
- 2009-11-13 SI SI200930543T patent/SI2358674T1/sl unknown
- 2009-11-13 TW TW098138705A patent/TWI441810B/zh active
- 2009-11-13 RU RU2011123890/04A patent/RU2503662C2/ru active
- 2009-11-13 AU AU2009313949A patent/AU2009313949B2/en not_active Ceased
- 2009-11-13 CA CA2739992A patent/CA2739992C/en active Active
- 2009-11-13 PT PT97529887T patent/PT2358676E/pt unknown
- 2009-11-13 ES ES09752988T patent/ES2397247T3/es active Active
- 2009-11-13 MX MX2011005090A patent/MX2011005090A/es active IP Right Grant
- 2009-11-13 RU RU2011123875/04A patent/RU2515612C2/ru active
- 2009-11-13 EP EP09752687A patent/EP2358674B1/en active Active
- 2009-11-13 CN CN200980145228.7A patent/CN102216272B/zh active Active
- 2009-11-13 TW TW098138704A patent/TWI461407B/zh active
- 2009-11-13 DK DK09752688.3T patent/DK2358675T3/da active
- 2009-11-13 WO PCT/US2009/064308 patent/WO2010056941A1/en active Application Filing
- 2009-11-13 JP JP2011536493A patent/JP5529150B2/ja active Active
- 2009-11-13 US US12/617,845 patent/US8247433B2/en active Active
- 2009-11-13 ES ES09752688T patent/ES2396583T3/es active Active
- 2009-11-13 BR BRPI0921593A patent/BRPI0921593B8/pt active IP Right Grant
-
2011
- 2011-04-10 IL IL212230A patent/IL212230A/en active IP Right Grant
- 2011-04-26 IL IL212452A patent/IL212452A0/en active IP Right Grant
- 2011-05-09 CO CO11056556A patent/CO6361988A2/es active IP Right Grant
- 2011-05-12 CL CL2011001088A patent/CL2011001088A1/es unknown
- 2011-05-12 ZA ZA2011/03495A patent/ZA201103495B/en unknown
- 2011-05-13 CL CL2011001093A patent/CL2011001093A1/es unknown
- 2011-05-25 CO CO11064614A patent/CO6361993A2/es active IP Right Grant
-
2012
- 2012-01-26 HK HK12100743.6A patent/HK1160449A1/xx not_active IP Right Cessation
- 2012-01-26 HK HK12100742.7A patent/HK1160448A1/xx unknown
- 2012-01-27 HK HK12100779.3A patent/HK1160452A1/xx unknown
- 2012-07-10 US US13/545,513 patent/US8802857B2/en active Active
- 2012-09-28 US US13/631,192 patent/US8604058B2/en active Active
- 2012-10-01 US US13/632,588 patent/US8592596B2/en active Active
- 2012-11-07 HR HRP20120897AT patent/HRP20120897T1/hr unknown
- 2012-11-13 HR HRP20120920AT patent/HRP20120920T1/hr unknown
- 2012-11-29 CY CY20121101168T patent/CY1113622T1/el unknown
- 2012-12-07 CY CY20121101189T patent/CY1113623T1/el unknown
- 2012-12-27 SM SM201200063T patent/SMT201200063B/it unknown
- 2012-12-28 SM SM201200065T patent/SMT201200065B/xx unknown
-
2013
- 2013-03-26 SM SM201300033T patent/SMT201300033B/xx unknown
- 2013-03-26 CY CY20131100256T patent/CY1113855T1/el unknown
- 2013-04-02 HR HRP20130300AT patent/HRP20130300T1/hr unknown
- 2013-10-23 US US14/060,846 patent/US9073859B2/en active Active
- 2013-11-04 US US14/070,887 patent/US9162982B2/en active Active
-
2014
- 2014-02-25 JP JP2014033727A patent/JP2014098033A/ja not_active Withdrawn
- 2014-03-07 JP JP2014044653A patent/JP2014101384A/ja not_active Withdrawn
- 2014-03-12 JP JP2014048387A patent/JP2014139209A/ja not_active Withdrawn
- 2014-07-08 US US14/325,863 patent/US9187423B2/en active Active
-
2015
- 2015-06-02 US US14/728,079 patent/US20160022660A1/en not_active Abandoned
- 2015-09-09 US US14/848,933 patent/US9675599B2/en active Active
-
2017
- 2017-05-04 US US15/586,531 patent/US10226454B2/en active Active
- 2017-05-10 US US15/591,419 patent/US10034870B2/en active Active
-
2018
- 2018-06-13 US US16/007,233 patent/US10206913B2/en active Active
-
2019
- 2019-01-03 US US16/239,265 patent/US10441579B2/en active Active
- 2019-01-10 US US16/244,956 patent/US10576073B2/en active Active
- 2019-06-11 AR ARP190101607A patent/AR114965A2/es unknown
- 2019-09-04 US US16/559,928 patent/US10722504B2/en active Active
-
2020
- 2020-01-16 US US16/744,551 patent/US10946006B2/en active Active
- 2020-06-17 US US16/903,579 patent/US10946007B2/en active Active
-
2021
- 2021-02-03 US US17/248,692 patent/US11723900B2/en active Active
- 2021-02-05 US US17/248,737 patent/US11596624B2/en active Active
-
2023
- 2023-02-28 US US18/115,436 patent/US20230201181A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2358675T3 (da) | 4-[2-(2-Fluorphenoxymethyl)phenyl]piperidinforbindelser | |
BRPI0817537A2 (pt) | 4-[3-(4-ciclopropanocarbonil-piperazina-i-carboni-,-fl uoro-benzil]-2h-ftalazin-1-ona | |
RU2465270C3 (ru) | Полиморфная форма 4-[3-(4-циклопропанкарбонилпиперазин-1-карбонил)-4-фторбензил]-2н-фталазин-1-она | |
DK2610258T3 (da) | Substituerede piperidindihydrothienopyrimidiner | |
ATE506359T1 (de) | Heteroaryl-substituierte piperidine | |
DK3564240T3 (da) | Piperidinmellemprodukter | |
ATE479681T1 (de) | Substituierte piperidine | |
BRPI0812923A2 (pt) | Derivados de piperidina/piperazina | |
BRPI0813331A2 (pt) | Derivados de piperidina/piperazina | |
BRPI1012055A2 (pt) | "piperidinas substituídas" | |
BRPI0913036A2 (pt) | contrapeso | |
DE602007012260D1 (de) | Nitratester von piperidinen | |
ZA201003031B (en) | 4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]benzoic acid-465 | |
BRPI1012775A2 (pt) | piperidinas substituídas | |
BRPI0916347A2 (pt) | compostos inseticidas de fenil ou piridil piperidina | |
ATE518857T1 (de) | Piperidin-amidderivate | |
BR112012003603A2 (pt) | [4-(5-aminometil-fenil)-piperidin-1il]-1hindol-3-il]-metanonas dissubstituídas | |
HK1140949A1 (en) | Liquid formulations of salts of 4-[2-(4-methylphenylsulfanyl) phenyl]piperidine 4-[2-(4-)-] | |
DK2181990T3 (da) | Piperidinderivat | |
BRPI0913396A2 (pt) | compostos de piperidina 3- ou 4-substituídos | |
BRPI0818552A2 (pt) | Piperidinas trissubstituídas | |
FI20085646A0 (fi) | Naulauskone | |
IT1391884B1 (it) | Cerniera reversibile | |
FIU20060472U0 (fi) | Kierrukkanostin |